Basic HTML Version
Table of Contents
View Full Version
Page 13 - FLIPBOOK
P. 13
Ipilimumab + Nivolumab vs Sunitinib INTERMEDIATE / POOR RISK Albiges L, et al. ESMO Open. 2020
8
9
10
11
12
13
14
15
16
17
18